Objective We examined whether a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, pioglitazone, suppresses coronary spasm.
Background Patients with coronary spastic angina (CSA) also have endothelial dysfunction and inflammation. Activation of PPAR-γ improves endothelial dysfunction and inflammation.
Participants and methods The study participants included 73 consecutive CSA patients (47 men and 26 women, mean age 63.6 ± 10.4 years) who were admitted to our institution with a suspicion of CSA because of episodes of chest discomfort occurring mostly at rest in whom coronary spasm was induced by an intracoronary acetylcholine injection and a repeat acetylcholine provocation injection was administered after 6 months of follow-up. Thirty-six of the patients were administered pioglitazone15-30 mg/day added on calcium channel blockers (CCBs) (pioglitazone group) and 37 were administered CCBs alone (control group). Clinical and laboratory data were also examined before and after 6 months of follow-up and the results between the two groups were compared.
Results Coronary spasm was suppressed in 18/36 patients (50.0%) in the pioglitazone group (P < 0.001) and 8/37 patients (21.6%) in the control group (P = 0.008) after 6 months of treatment. Coronary spasm was thus significantly reduced in the pioglitazone group compared with the control group (P = 0.011). The levels of total white blood cell count and high-sensitivity C-reactive protein decreased significantly (P < 0.001 and P < 0.001, respectively) in the pioglitazone group, whereas these levels did not differ in the control group (P = 0.15 and 0.39, respectively) after the treatment.
Conclusion Pioglitazone added on CCBs significantly reduced coronary spasm compared with CCBs alone after 6 months of treatment. Pioglitazone may thus prove to be a novel therapy for coronary spasm. 
Introduction
Coronary spasm plays an important role in the pathogenesis of CHD and is prevalent among Japanese patients [1] [2] [3] . Patients with coronary spasm or coronary spastic angina (CSA) show endothelial dysfunction and low-grade inflammation [1, 4, 5] . Pioglitazone, a thiazolidinedione (TZD) and peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, improves insulin resistance and is used widely for the treatment of type 2 diabetes mellitus [6] [7] [8] . There is increasing evidence that PPAR-γ activation improves endothelial dysfunction, vasoconstriction, and inflammation as well as insulin resistance [9, 10] . Patients with CSA also show insulin resistance [11] [12] [13] . It is therefore possible that pioglitazone may also ameliorate coronary spasm by improving endothelial dysfunction, inflammation, and insulin resistance. Calcium channel blockers (CCBs) have been shown to be highly effective in suppressing coronary spasm and are used as the standard therapy for coronary spasm [1, 3] .
However, a considerable number of CSA patients are resistant to CCBs even in high doses, and lethal arrhythmias and/or sudden death occur in some of them [1, 3] . Moreover, CSA often recurs on withdrawal of CCBs [1, 3, 14] . The present study was designed to examine whether the addition of pioglitazone to the conventional CCB therapy would result in greater reduction in coronary spasm compared with the conventional CCB therapy.
Participants and methods

Study participants
The study participants were 73 consecutive patients (47 men and 26 women, mean age 63.1 10.4), in whom coronary spasm was angiographically documented by an intracoronary infusion of acetylcholine (ACh) and who had agreed and adhered to the protocol of this study at our institution. These patients underwent coronary angiography with the ACh test on suspicion of CSA because of recurrent chest discomfort at rest and preserved exercise capacity. This was an open-label study evaluating the efficacy of pioglitazone on coronary spasm. Thirty-six of the patients were administered pioglitazone 15-30 mg/ day plus CCBs (slow-release diltiazem 100-200 mg/day and slow-release nifedipine 20-40 mg/day) (the pioglitazone group) between January 2012 and February 2014. Thirty-seven of the patients had been administered CCBs alone (the control group) between January 2002 and December 2008 for 6 months and the intracoronary ACh provocation test for coronary spasm was again performed thereafter. Thirty-three patients in the control group of the previous report [14] were added to the control group because it was difficult to recruit a sufficient number of control patients. Patients with previously established DM were excluded from the study. Patients with acute myocardial infarction, organic coronary stenosis of at least 75%, left main trunk lesion, three-vessel disease, uncontrolled arrhythmias, heart failure, resting hypertension more than 180/110 mmHg, acute systemic illness, hepatic or renal insufficiency, and other severe conditions were excluded from the study. Hypertension was defined as 140/90 mmHg and diabetes mellitus as fasting plasma glucose level more than 126 mg/dl or plasma glucose level more than 200 mg/dl at 2 h on 75 g oral glucose tolerance test.
The intracoronary ACh test for coronary spasm was again performed after 6 months of drug administration. The study was approved by the ethics committee of our institution and written informed consent was obtained from each patient.
Provocation of coronary spasm
Coronary spasm was defined as total or subtotal obstruction, or severe diffuse vasoconstriction of an epicardial coronary artery associated with transient ischemic changes on ECG. CCBs and other vasoactive medications were discontinued for at least 5 days, except sublingual nitroglycerin, which was also withdrawn 8 h before coronary angiography. Coronary spasm was induced by an intracoronary injection of ACh (Daiichi-Sankyo Co., Tokyo, Japan) after diagnostic catheterization in the morning. The details of the method have been reported previously [15] . ACh dilates human coronary arteries by stimulating endothelial nitric oxide, but constricts those with endothelial dysfunction [15, 16] . Briefly, ACh was injected in incremental doses of 10, 20, 50, and 100 μg into the left coronary artery (LCA) and then 10, 20, and 50 μg into the right coronary artery (RCA) with continuous monitoring of ECG and blood pressure. Coronary spasm induced by this method usually disappeared spontaneously within 1-2 min and both the LCA and the RCA could be examined separately unless severe spasm occurred in the LCA and necessitated the prompt injection of isosorbide dinitrate (ISDN) into the arteries. After the end of the test, ISDN (0.1 mg) was injected into the coronary artery and angiography was performed again. The test did not induce coronary spasm in any of the patients with normal coronary angiogram and without ischemic heart disease [15] . Significant organic coronary stenosis was defined as more than 50% luminal diameter and organic coronary artery disease was divided into one-vessel, two-vessel, and three-vessel disease.
Treatment and follow-up
Each patient was evaluated every month for 6 months for assessment of drug compliance, ECG, lipid profile, and safety markers. At the 6-month follow-up, patients again underwent the intracoronary ACh test for coronary spasm after withdrawal of CCBs for about a week. Care was taken to replicate angiographic views, catheter positions, and the order of infusions used in the baseline study. We did not administer statins to the patients during the study periods because of the beneficial effects of statins on coronary spasm [14] .
Assessment of coronary artery diameter and electrocardiographic changes
Severe coronary spasm to a residual lumen diameter of less than 0.4 mm could not be quantified accurately because of technical limitations of the computer-assisted quantitative coronary angiography [17] . However, the spasm sites at baseline were identified and the same segments were evaluated quantitatively at the submaximal dose of ACh (50 μg) in the LCA at baseline and follow-up at the laboratory. Each segment was referenced to a specific anatomic landmark for identification and films from the baseline and follow-up were examined at the same time to ensure analysis of the identical portion of the vessel. The measurement was blinded to the ECG findings and the medications. An end-diastolic frame was digitized and the diameter of the index vessel was measured using CAAS II software (PIE Medical Imaging, Maastricht, Limburg, the Netherlands). The coronary response to ACh was expressed as the percentage change from that on ISDN in lumen diameter and was compared at the same site of the same artery before and after 6 months of treatment. The ECG was examined in a blinded manner as to the coronary angiographic findings and the medications.
Oral glucose tolerance test
The oral glucose tolerance test was performed and the homeostasis model assessment of insulin resistance index as a measure of insulin resistance in the fasting state, insulin sensitivity index, and log post-glucose-insulin resistance as a measure of insulin resistance on oral glucose load, and insulinogenic index as an index of β-cell function were calculated in the pioglitazone group as reported previously [13] .
Evaluation of endothelial function
Endothelial function was assessed as flow-mediated dilatation (FMD) of the brachial artery in the pioglitazone group. The details of the method have been reported previously [18] . Briefly, the patients arrived at the laboratory at a similar time of day (7:00-8:00 a.m.) under fasting and after avoiding exercise, smoking, alcohol, or antioxidant vitamins for at least 12 h. FMD was evaluated using a 10 mHz linear array transducer probe attached to a high-resolution vascular ultrasound machine with an edge detection and edge tracking system for automatic measurement (UNEXEF 18G; UNEX Corporation, Nagoya, Japan). FMD was estimated as the percent change in the diameter over the baseline value at the maximal dilatation during reactive hyperemia. The mean intra-assay and interassay coefficients of variation measure in 20 individuals were 8.1 and 10.4%, respectively.
Blood chemistry measurements
Blood samples for measurement of blood chemistry data were collected in the supine position after an overnight fast. Plasma glucose was measured by the glucose oxidase method using the Synchron System Glucose Kit on an Automatic Clinical Analyzer (Beckman Coulter Co., Tokyo, Japan). Plasma insulin was measured using the HISCL Insulin assay kit on the basis of the chemiluminescence enzyme immunoassay on an Automated Immunoassay System HISCL-5000 (Sysmex Co., Kobe, Japan). Serum high-sensitivity C-reactive protein (hsCRP) levels were measured in duplicate by an automated immunoturbidimetric assay using the Synchron LX20 Prosystem (Beckman Coulter, Tokyo, Japan). The lower limit of this assay was 0.2 mg/l, with intra-assay and interassay coefficients of variation of less than 5.0% at 0.25 mg/l of CRP. The total white blood cell (WBC) count and the differential WBC count were assessed by the Coulter principle using Beckman Coulter UniCel DxH800 and Coulter LH 750 (Beckman Coulter, Miami, Florida, USA). Plasma HDL cholesterol was measured using the MetaboLead HDL-C Kit (Kyowa Medics Co., Tokyo, Japan). Other biochemical analyses were carried out using standard laboratory procedures.
Statistical analysis
The primary end point of the study was ACh-induced coronary spasm 6 months after the treatment. We hypothesized that the induction rate of coronary spasm would be different after pioglitazone compared with the control. The sample size (number of patients) was calculated on the basis of a z-test at the two-sided 5% significance level and 80% power. A 30% treatment effect was considered to be clinically significant, assuming a recurrence rate of coronary spasm to be 80-90% without medications. The secondary end point was the coronary artery diameter change in response to the submaximal dose (50 μg) of ACh. For continuous variable, differences between groups were evaluated using an unpaired t-test or the Mann-Whitney rank-sum test, and those within group using a paired t-test or the Wilcoxon signed-rank test. For discrete variables, differences were expressed as counts and percentages and were analyzed using the χ 2 (or Fisher exact) test between groups and with the McNemar test or the Fisher exact test within groups as appropriate. A twotailed P value of less than 0.05 was considered to be statistically significant. Data were expressed as mean SD. However, when the variable was significantly skewed, the median (25th-75th percentile) was reported. The analyses were carried out using the SPSS software (IBM SPSS Statistics for Windows, Version 19.0; IBM Corp., Armonk, New York, USA).
This study was investigator initiated and the drug makers had no direct or indirect involvement in the design of the study, provision of the drug, data collection, or preparation of the manuscript.
Results
Clinical characteristics and adverse events
The baseline characteristics of the two treatment groups are shown in Table 1 . There were no differences in the clinical characteristics at baseline between the two groups. Thirty-two patients in the pioglitazone group and 31 patients of the control group had episodes of chest discomfort 1 month before entry. Twenty-four of the patients (75.0%, P < 0.001) in the pioglitazone group and 23 of the patients (74.2%, P < 0.001) in the control group became asymptomatic during 6 months of follow-up treatment with no changes in medications and doses. Thus, CCBs were highly effective in suppressing symptomatic coronary spasm in both groups in agreement with the previous studies [1] [2] [3] [4] , and there was no significant difference (P = 0.94) in the incidence of subjective symptoms during the 6 months of the follow-up treatment period between the two groups. Edema and nocturia occurred in three (8.3%) and five (13.9%) of the patients in the pioglitazone group. No other adverse effects including heart failure were detected during the follow-up in both groups.
Coronary angiographic and electrocardiographic findings
At baseline, spasm was induced at 36 left anterior descending (LAD) artery, 14 left circumflex artery, and 26 RCA in the pioglitazone group and 37 LAD, 15 left circumflex artery, and 20 RCA in the control group. After 6 months of treatment and on withdrawal of CCBs for about a week, spasm was induced at 18 LAD (100.0-50.0%, P < 0.001) in the pioglitazone group and 29 LAD (100-78.4%, P = 0.008) in the control group (Fig. 1) . Coronary spasm was therefore suppressed in 18/36 patients (50.0%, P < 0.001) in the pioglitazone group and in 8/37 patients (21.6%, P = 0.008) in the control group after 6 months of treatment. Accordingly, the number of patients with ACh-induced coronary spasm was significantly reduced in the pioglitazone group compared with the control group (50.0 vs. 21.6%, P = 0.011) (Fig. 1) . The results also indicated that coronary spasm was induced in a high proportion of the patients after .089] in the control group. Accordingly, there was a significant reduction in the constrictor response to ACh in the pioglitazone group compared with the control group after 6 months of treatment (P = 0.008) (Fig. 2) . The ischemic ECG changes at the intracoronary ACh 50 μg decreased significantly after treatment in the pioglitazone group, but not in the control group (P = 0.004 and 0.125, respectively) ( Table 2) .
Flow-mediated dilatation
FMD increased significantly from 4.2 2.1 to 5.1 2.1% (P = 0.015) after the treatment compared with the baseline, indicating the improved endothelial function in the pioglitazone group (Table 3) . Values are represented as n (%), median (25%, 75%), and mean SD. ACE inhibitor, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; CPK, creatine phosphokinase; HDL-cholesterol, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-cholesterol, low-density lipoprotein cholesterol. Coronary artery diameter change in response to acetylcholine (ACh) injection. Response of coronary artery diameter to an intracoronary injection of ACh 50 μg improved compared with that at baseline in the pioglitazone group, but did not improve in the control group after 6 months of treatment.
Clinical and laboratory data
Clinical and laboratory data in the two groups at the baseline and after the treatment are shown in Table 3 . Systolic blood pressure, blood levels of WBC, RBC, platelet, hsCRP, glucose, uric acid, and alanine aminotransferase decreased significantly (P = 0.002, P < 0.001, P = 0.002, P = 0.013, P < 0.001, P = 0.001, P = 0.003, and P = 0.002, respectively) and HDL-cholesterol increased significantly (P = 0.004) in the pioglitazone group, whereas these levels remained unchanged in the control group. Insulin sensitivity index and log post-glucoseinsulin resistance increased significantly (P < 0.001 and P <0.001, respectively) after the treatment in the pioglitazone group.
These results indicated that pioglitazone reduced blood pressure and improved inflammation, oxidative stress, and lipid profiles as well as insulin sensitivity. We did not perform FMD and the oral glucose tolerance test after 6 months in the control group.
Discussion
Coronary spasm plays an important role in the pathogenesis of CHD and is prevalent among Japanese patients [1] [2] [3] . However, the mechanisms underlying coronary spasm remain to be elucidated [1] [2] [3] 19] . CCBs are established as the standard therapy for coronary spasm [1, 3] . However, coronary spasm may not be controlled even with high doses of CCBs in a considerable number of patients [1, 3] .
The present study showed that the number of patients with coronary spasm decreased significantly in the pioglitazone group compared with the control group. The quantitative angiographic analysis showed that the coronary constrictor response to a submaximal dose (50 μg) of ACh was ameliorated significantly in the pioglitazone group compared with the control group, implying that pioglitazone improved coronary endothelial dysfunction. The levels of WBC count, hsCRP, glucose, uric acid, alanine aminotransferase, and lipid profiles improved significantly after treatment in the pioglitazone group, whereas these levels remained unchanged in the control group. These findings indicate that pioglitazone, which is an agonist of PPAR-γ and is widely used for the treatment of type 2 diabetes mellitus [6] [7] [8] , also suppresses inflammation and oxidative stress as well as insulin resistance. PPAR-γ is expressed in the vasculature as well as adipocytes, macrophages, and lymphocytes and improves endothelial dysfunction and inflammation as well as insulin resistance [9, 10, 20] . Activation of PPAR-γ also blocks activation of the RhoA/RhoA-associated kinase (ROCK) pathway, which enhances contractility of vascular smooth muscle by increasing calcium sensitivity [21] [22] [23] .
Coronary spasm may be considered an abnormal hypercontraction of coronary vascular smooth muscle [1, 3] and accumulating evidence indicates that hypercontraction of vascular smooth muscle is mainly caused by the enhanced Ca 2 + sensitization through the activation of the RhoA/ROCK pathway [1, 3, 23, 24] . Accordingly, it is reasonable to postulate that PPAR-γ agonists including pioglitazone are likely to suppress coronary spasm by inhibiting the RhoA/ROCK pathway, thereby improving endothelial function and NO activity and suppressing inflammation and Ca 2 + sensitivity of coronary smooth muscle.
The present study thus suggested that pioglitazone may prove to be a novel therapeutic drug for coronary spasm as well as type 2 diabetes mellitus. Indeed, pioglitazone has been shown to reduce the composite end point of allcause death, myocardial infarction, and stroke compared with control [8, 9, [25] [26] [27] . However, TZDs including pioglitazone have adverse side effects such as weight gain, fluid retention, heart failure, bone loss, and possibly bladder cancer [6, 8, 20] , and rosiglitazone, another TZD, has been reported to increase cardiovascular events [28] . Thus, whether PPAR-γ agonists including pioglitazone are beneficial for the treatment of coronary spasm would require long-term follow-up.
Study limitations
Although the present study showed that the addition of pioglitazone to the standard CCB therapy suppresses coronary spasm, the duration of the study period was short (6 months) and the number of the study participants was small because of the invasive nature of the study. This was a hypothesis-proving pilot study and a prospective randomized controlled trial including a large number of patients and longer periods of follow-up would be required to definitely determine the long-term efficacy of pioglitazone for the treatment of coronary spasm.
Conclusion
The present study showed that an addition of pioglitazone to the standard CCB therapy for 6 months significantly reduced coronary spasm induced by an intracoronary injection of ACh compared with the standard therapy.
